Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7493-7501

  Honeychurch, Jamie ^a   Glennie, Martin J ^a   Illidge, Timothy M ^b,c  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; NITRIC OXIDE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11B; ANTIGENS, CD40; APOPTOSIS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; NITRIC OXIDE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 23844534037     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3808     Document Type: Article

References (42)

1. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000;21:403-10.
2. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
3. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42.
5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
6. Kim DW, Choy H. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:11-20.
7. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-6.
8. Hill DL. A review of cyclophosphamide. Springfield, IL: C.C. Thomas Publisher; 1975.
9. Mitsuoka A, Baba M, Morikawa S. Enhancement of delayed hypersensitivity by depletion of suppressor T-cells with cyclophosphamide in mice. Nature 1976; 262:77-8.
10. Tsung K, Meko JB, Tsung YL, Peplinski GR, Norton JA. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J Immunol 1998;160:1369-77.
11. Vierboom MP, Bos GM, Ooms M, Offringa R, Melief CJ. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int J Cancer 2000; 87:253-60.
12. Fosdick WM, Parsons JL, Hill DF. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 1968;2:151-61.
13. Tutt AL, French RR, Illidge TM, et al. Monoclonal antibody therapy of B cell lymphoma: signalling activity on tumor cells appears more important than recruitment of effectors. J Immunol 1998;161:3176-85.
14. Grewal IS, Flavell RA. Anti-CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16: 111-35.
15. French RR, Chan HTC, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-53.
16. Tutt AL, O'Brien L, Hussain A, Crowther GR, French KR, Glennie MJ. T-cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 2002;168:2720-8.
17. Honeychurch J, Glennie MJ, Johnson PWM, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell dependent immunity to B-cell lymphoma. Blood 2003;102:1449-57.
18. Slavin S, Strober S. Spontaneous murine B cell leukaemia. Nature 1977;272:624-6.
19. 1. Cancer Biother Radiopharm 2000;15: 571-80.
20. Hasbold J, Johnson-Leger C, Atkins CJ, Clark EA, Klaus GGB. Properties of mouse CD40: cellular distribution of CD40 and B-cell activation by monoclonal anti-mouse CD40 antibodies. Eur J Immunol 1994;24:1835-42.
21. Tomonari K. A rat antibody against a structure functionally related to the mouse T-cell receptor/T3 complex. Immunogenetics 1988;28:455-8.
22. Cobbold SP, Martin G, Waldmann H. The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J Immunol 1990;20:2747-55.
23. Peto R. Editorial: guidelines on the analysis of tumor rates and death rates in experimental animals. Br J Cancer 1974;29:101-5.
24. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001;5: 62-71.
25. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of PS expression on early apoptotic cells using fluoroscein labelled annexin V. J Immunol Methods 1995;184:39-51.
26. + cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 2000;95;212-20.
27. Kusmartsev SA, Li Y, Chen S-H. Gr-I+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000;165:779-85.
28. Brooks-Kaiser JC, Bourque LA, Hoskin DW. Heterogeneity of splenic natural, suppressor cells induced in mice by treatment with cyclophosphamide. Immunopharmacology 1993;25:117-29.
29. Serge M, Tomei E, Segre D. Cyclophosphamide-induced suppressor cells in mice: suppression of the antibody response in vitro and characterization of the effector cells. Cell Immunol 1985;91:443-54.
30. Scmidt-Wolf IG, Dejbarhsh S, Ginzton N, Greenberg P, Strober S. T-cell subsets and suppressor cells in human bone marrow. Blood 1992;80: 3242-50.
31. Young MRJ, Wright MA, Matthews P, Malik J, Pandit R. Suppression of T-cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-B and nitric oxide. J Immunol 1996;156:1916-22.
32. Mantovani A, Luini W, Peri G, Vecchi A, Spreafico F. Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice. J Natl Cancer Inst 1978; 5:1255-61.
33. Angulo I, Rodriguez R, Garcia B, Medina M, Navarro J, Subiza JL. Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-γ. J Immunol 1995;155:15-26.
34. Allione A, Bernabei P, Bosticardo M, Ariotti S, Forni G, Novelli F. Nitric oxide suppresses human T lymphocyte proliferation through IFN-γ-dependent and IFN-γ-independent induction of apoptosis. J Immunol 1999; 163:4182-91.
35. + T-cell response by dysregulating antigen-presenting cell maturation. J Immunol 1999;162:5728-37.
36. Angulo I, Rullas J, Campillo JA, et al. Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN-g stimulation through a mechanism dependent on endogenous TNF-α and IL-1α. Eur J Immunol 2000;30: 1263-71.
37. Stout RD, Suttles J, Xu J, Grewal IS, Flavell RA. Impaired T cell-mediated macrophage activation in CD40 ligand deficient mice. J Immunol 1996; 156:8-11.
38. Bonham CA, Lu L, Li Y, Hoffman RA, Simmons RL, Thompson AW. Nitric oxide production by bone marrow-derived dendritic cells: implications for the regulation of allogeneic T-cell responses. Transplantation 1996;62:1871-7.
39. Schiavoni G, Mattei F, Di Pucchio T, et al. Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000;95:2024-30.
40. Proietti E, Greco G, Garrone B, et al. Importance of cyclophosphamide- induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 1998; 101:429-41.
41. Inagawa H, Nishizawa T, Honda T, Nakamoto T, Takagi K, Soma G. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res 1998;18:3957-64.
42. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003;63:8408-13.